Sanofi-Aventis SA Chief Executive Chris Viehbacher provided a possible price range of $69 to $80 a share to buy Genzyme Corp. at a Sept. 20 meeting with the U.S. company’s chief, Genzyme said.
Henri Termeer, the Genzyme CEO, declined to agree to the range, Cambridge, Massachusetts-based Genzyme said in a regulatory filing yesterday. Sanofi today denied making such a proposal. “We offered no price range and Genzyme continued to refuse to engage with us on valuation,” Sanofi spokesman Jean-Marc Podvin said by telephone today.
